ClinicalTrials.gg
Active, not recruitingNCT03512405Updated Nov 17, 2026Results posted

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia

A Phase 1/2 interventional study of Blinatumomab and Laboratory Biomarker Analysis in CD19 Positive, Philadelphia Chromosome Positive and Recurrent Acute Lymphoblastic Leukemia, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by City of Hope Medical Center · Phase 1/2, Interventional, and Treatment

How we know · 10 judgments

Updated Nov 17, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
48th of 61
26 · median 67
Started
2019
with 3 others
Phase 1/2
8 of 61
2 open now
Primary completion
2025-01
later than 4 of 38 live
Registered
22nd of 61
by date

Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 48th largest by enrollment, is one of 4 that started in 2019, is one of 8 in phase 1/2, reaches primary completion later than 4 of the 38 other live ones, and was the 22nd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

This phase I/II studies the side effects of pembrolizumab and blinatumomab and to see how well they work in treating participants with acute lymphoblastic leukemia that has come back or has not responded to the treatment. Monoclonal antibodies, such as pembrolizumab and blinatumomab, may interfere with the ability of tumor cells to grow and spread.

Read the detailed description

PRIMARY OBJECTIVES:

I. Assess the safety and tolerability of combination immunotherapy with blinatumomab and pembrolizumab by evaluation of toxicities including: type, frequency, severity, attribution, time course and duration. (Phase 1) II. Determine the recommended phase 2 schedule of combination immunotherapy with pembrolizumab and blinatumomab. (Phase 1) III. Evaluate the anti-leukemia activity of combination immunotherapy blinatumomab and pembrolizumab as assessed by overall response rate (complete response [CR] or CR with incomplete recovery [CRi]). (Phase 2)

SECONDARY OBJECTIVES:

I. Estimate time to response (CR or CRi) and response duration. (Phase 2) II. Estimate overall survival and event-free survival. (Phase 2) III. Determine the number and proportion of patients who underwent hematopoietic stem cell transplantation (HSCT) after treatment of pembrolizumab and blinatumomab. (Phase 2) IV. Determine the number and proportion of patients who receive pembrolizumab maintenance and the proportion continuing for up to 1 year. (Phase 2) V. Estimate the minimal residual disease rate. (Phase 2)

CORRELATIVE OBJECTIVES:

I. Explore evolution of T cell subsets at various points in treatment (T naive, T effector, T effector memory, T central memory, CD4, CD8). (Phase 2) II. Evaluate PD-L1 expression levels on acute lymphoblastic leukemia (ALL) blasts and blasts counts overtime. (Phase 2) III. Evaluate PD-1/PD-L1 expression on subsets of T cells. (Phase 2) IV. Evaluate the clonal evolution of leukemic blasts in response to treatment. (Phase 2)

OUTLINE:

Participants receive pembrolizumab intravenously (IV) over 30 minutes on day 15 of cycle 1 and days 1 and 22 of cycles 2 -5, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response have the option to receive blinatumomab IV for up to 4 additional cycles.

After completion of study treatment, participants are followed up at 30 days and then every 3 months for 1 year.

03

Conditions studied

  • CD19 Positive
  • Philadelphia Chromosome Positive
  • Recurrent Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously treated ALL including philadelphia chromosome (BCR-Ab1) positive ALL who meet all of the following criteria:

    • Diagnosis of CD19-positive B-cell ALL based on the flow cytometry and histology
    • Previously treated subjects with primary disease OR after first or subsequent relapse
    • Subjects with detectable lymphoblasts in bone marrow (BM) or extramedullary disease (EMD) that is radiographically measurable and amenable to repeat
  • (ECOG) performance status 0 or 1
  • (LVEF) > 45%
  • Pulmonary function tests diffusing capacity of the lungs for carbon monoxide (DLCO) (adjusted for ) > 50% predicted
  • Serum creatinine =\< 1.5 X (ULN) OR measured or calculated ( [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 ml/min for subject with creatinine levels > 1.5 X institutional ULN
  • Serum total =\< 1.5 X ULN OR direct bilirubin =\< ULN for subjects with total bilirubin levels > 1.5 ULN
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine transaminase (serum glutamic pyruvic transaminase [SGPT]) =\< 2.5 X ULN OR =\< 5 X ULN for subjects with liver
  • Albumin >= 2.5 mg/dL
  • (INR) or prothrombin time (PT) =\< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
  • Activated partial thromboplastin time (aPTT) =\< 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  • Beta human chorionic gonadotropin (beta HCG) negative
  • (HIV): negative HIV antibody / polymerase chain reaction (PCR)
  • virus (HBV): negative hepatitis B surface antigen (HBsAg) and negative hepatitis B core (HBc) antibody or positive HBc and negative HBV deoxyribonucleic acid (DNA) by quantitative PCR
  • virus (HCV): negative viral ribonucleic acid (RNA) (if HCV antibody is positive)
  • Required screening laboratory data (within 28 days prior to administration of pembrolizumab)
  • Discontinuation of all therapy (including radiotherapy, chemotherapy, tyrosine-kinase inhibitors [TKIs], immunotherapy or therapy) for the treatment of cancer as follows:

    • At least 1 week or 5 half-lives (whichever is longer) from the last dose of prior anti-cancer therapy and the initiation of study therapy
    • Exceptions or modifications to the above are as follows:

      • Medications that are typically part of a maintenance therapy for ALL, such as or mercaptopurine, may be administered up to 3 days prior to the first dose, except vinca alkaloids which must be discontinued at least 14 days prior to the start of study treatment; TKIs are not permitted to be continued at screening (e.g. Gleevec)
    • Intrathecal (IT) chemotherapy may be dosed up to 7 days prior to first dose of pembrolizumab (cytarabine [Ara-C] recommended)
    • For biologics (e.g. monoclonal antibodies), of 1 month beyond the recommended dosing interval and at least 4 weeks or 5 half-lives (whichever is longer) since the last dose
  • All acute toxic effects of any prior antitumor therapy must be resolved to grade =\< 1 before enrollment, with the exception of alopecia (any grade permitted), or bone marrow parameters (any grades permitted)
  • For female subjects of , willingness to abstain from heterosexual intercourse or use 2 concurrent protocol recommended methods of from the screening visit throughout the study treatment period and to 30 days from the last dose of pembrolizumab; a negative serum pregnancy test is required for female subjects at screening; lactating females must agree to discontinue nursing before administration of study drugs
  • For male subjects having intercourse with females of childbearing potential, willingness to abstain from heterosexual intercourse or use 2 protocol-recommended methods of contraception from the start of pembrolizumab throughout the study treatment period and for 90 days following the last dose of pembrolizumab; also, male subjects should refrain from sperm donation from the start of pembrolizumab throughout the study treatment period and for 3 months following the last dose of study drugs
  • In the judgment of the investigator, participation in the protocol offers an acceptable benefit-to-risk ratio when considering current disease status, medical condition, and the potential benefits and risks of alternative treatments for the subject's ALL
  • Willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions; psychological, social, familial or geographical factors that might preclude adequate study participation should be considered
  • Have the ability to understand and sign a written form, which must be obtained prior to initiation of study procedures

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of mature B-cell ALL (Burkitt's leukemia) according to World Health Organization (WHO) classification, or lymphoid blast crisis of chronic myelogenous leukemia (CML)
  • A life threatening illness, medical condition or organ system dysfunction which, in the investigators' opinion, could compromise the subject's safety or interfere with the absorption or metabolism of pembrolizumab
  • Active or symptomatic central nervous system (CNS) disease

    • For study purposes, a subject will not be considered as having active CNS disease if the subject has documentation of prior CNS disease and has received prior treatment (IT or radiation) and is:

      • Asymptomatic for the last 28 days prior to screening and
      • Has documented at least 2 negative cerebrospinal fluid (CSF) cytology (which must include 1 lumbar puncture [LP] within the study screening window)
  • Uncontrolled undercurrent illness including but not limited to unstable angina pectoris or psychiatric illness/social situations that would limit compliance with study requirements; subjects with active infection are permitted to enroll provided that the infection is documented to be under control
  • History of myelodysplastic syndrome or organ transplantation
  • History of non-lymphoid except for the following:

    • Adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known disease and with no requirement for therapy or requirement only hormonal therapy and with normal prostate specific antigen for > 1 year prior to the start of pembrolizumab, or any other cancer that has been in complete remission without treatment for >= 5 years prior to enrollment
  • Known or intolerance to any of the active substance or in the formulations for pembrolizumab and blinatumomab
  • Ongoing drug-induced liver injury, chronic active (HCV), chronic active (HBV), , alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, or portal hypertension
  • Prior bone marrow transplantation
  • Pregnancy or breastfeeding
  • Has known history of, or any evidence of active, non-infectious pneumonitis
  • Concurrent participation in an drug trial with therapeutic intent defined as prior study therapy within 28 days prior to start of this study
  • Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =\< grade 1 or at baseline) from adverse events due to a previously administered agent

    • Note: subjects with =\< grade 2 neuropathy are an exception to this criterion and may qualify for the study
    • Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
  • Has active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, or drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
  • Has received prior therapy with an , anti-PD-L1, or anti-PD-L2 agent or blinatumomab
  • Has received a within 30 days of planned start of study therapy
  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Treatment (pembrolizumab, blinatumomab)

    Participants receive pembrolizumab intravenously (IV) over 30 minutes on day 15 of cycle 1 and days 1 and 22 of cycles 2 -5, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response have the option to receive blinatumomab IV for up to 4 additional cycles.

    Biological: Blinatumomab · Other: Laboratory Biomarker Analysis · Biological: Pembrolizumab

Interventions

  • BiologicalBlinatumomab

    Given IV

    Also known as: Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MT-103

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • BiologicalPembrolizumab

    Given IV

    Also known as: Keytruda, Lambrolizumab, MK-3475, SCH 900475

06

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicity (Phase 1)

    Number of participants experiencing at least one dose-limiting toxicity (DLT) during the DLT assessment period. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From the start of initial treatment up to 35 days

  2. Response Rate (Phase 2)

    Response was defined as complete response (CR)/CR with incomplete hematologic recovery (CRi) based on the National Comprehensive Cancer Network guidelines on acute lymphoblastic leukemia version 1 2017 response criteria.

    Time frame: From the start of initial treatment till the end of protocol treatment, up to 5 cycles

Secondary outcomes

  1. Incidence of Grade 3-5 Adverse Events

    Toxicities were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0. Number of participants experiencing at least one Grade 3, 4, or 5 adverse event.

    Time frame: From the start of initial treatment until protocol completion, up to 24 months after the end of treatment.

  2. Duration of Remission

    Duration of remission is defined as the time from first documented complete response (CR) or complete response with incomplete hematologic recovery (CRi) to the earliest of disease progression or the end of protocol follow-up.

    Time frame: From the date of first documented CR/CRi until disease progression or the end of protocol follow-up, whichever occurs first.

  3. Time to Response

    Time to response is defined as the time from the first dose of study treatment to the first documented objective response (complete response \[CR\] or complete response with incomplete hematologic recovery \[CRi\]).

    Time frame: From date of first dose of study drug up to the end of study treatment

  4. Median Overall Survival

    Overall survival is defined as the time from first dose of study treatment to death from any cause. Median overall survival was estimated using the Kaplan-Meier method

    Time frame: From date of first dose of study drug up to 1 year

  5. Incidence of Relapse

    Incidence of relapse is defined as the number of participants who experienced disease relapse after achieving a documented response (complete response \[CR\] or complete response with incomplete hematologic recovery \[CRi\]) during the protocol-defined follow-up period.

    Time frame: From date of first dose of study drug up to 1 year

  6. Allogeneic Stem Cell Transplantation (SCT) Realization Rate

    Allogeneic stem cell transplantation (SCT) realization rate was measured by number and proportion of patients who underwent SCT after treatment of pembrolizumab and blinatumomab.

    Time frame: From the end of study treatment through 1 year.

  7. Number and Proportion of Patients Who Start Pembrolizumab Maintenance

    Time frame: Up to 1 year

  8. Number and Proportion of Patients Who Complete Pembrolizumab Maintenance

    Time frame: Up to 1 year

  9. Minimal Residual Disease Rate

    Minimal residual disease (MRD) was measured by number and proportion of patients with CR/CRi who had confirmed minimal residual disease.

    Time frame: From the end of study treatment through 1 year.

07

Results

Posted Nov 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIVSchedule B: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Started260
Completed240
Not completed20
Withdrew: Lack of efficacy20

Outcome measures

PrimaryIncidence of Dose-Limiting Toxicity (Phase 1)

Number of participants experiencing at least one dose-limiting toxicity (DLT) during the DLT assessment period. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Time frame:
From the start of initial treatment up to 35 days
Reported as:
Count of participants · Participants
Incidence of Dose-Limiting Toxicity (Phase 1)
ParticipantsSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Incidence of Dose-Limiting Toxicity (Phase 1)0
PrimaryResponse Rate (Phase 2)

Response was defined as complete response (CR)/CR with incomplete hematologic recovery (CRi) based on the National Comprehensive Cancer Network guidelines on acute lymphoblastic leukemia version 1 2017 response criteria.

Time frame:
From the start of initial treatment till the end of protocol treatment, up to 5 cycles
Reported as:
Count of participants · Participants
Response Rate (Phase 2)
ParticipantsSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Response Rate (Phase 2)17
SecondaryIncidence of Grade 3-5 Adverse Events

Toxicities were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0. Number of participants experiencing at least one Grade 3, 4, or 5 adverse event.

Time frame:
From the start of initial treatment until protocol completion, up to 24 months after the end of treatment.
Reported as:
Count of participants · Participants
Incidence of Grade 3-5 Adverse Events
ParticipantsSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Incidence of Grade 3-5 Adverse Events24
SecondaryDuration of Remission

Duration of remission is defined as the time from first documented complete response (CR) or complete response with incomplete hematologic recovery (CRi) to the earliest of disease progression or the end of protocol follow-up.

Time frame:
From the date of first documented CR/CRi until disease progression or the end of protocol follow-up, whichever occurs first.
Reported as:
Median · months
Duration of Remission
monthsSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Duration of RemissionNA (11.4 to NA)
SecondaryTime to Response

Time to response is defined as the time from the first dose of study treatment to the first documented objective response (complete response \[CR\] or complete response with incomplete hematologic recovery \[CRi\]).

Time frame:
From date of first dose of study drug up to the end of study treatment
Reported as:
Median · months
Time to Response
monthsSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Time to Response0.9 (0.9 to 2.3)
SecondaryMedian Overall Survival

Overall survival is defined as the time from first dose of study treatment to death from any cause. Median overall survival was estimated using the Kaplan-Meier method

Time frame:
From date of first dose of study drug up to 1 year
Reported as:
Median · months
Median Overall Survival
monthsSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Median Overall SurvivalNA (15.6 to NA)
SecondaryIncidence of Relapse

Incidence of relapse is defined as the number of participants who experienced disease relapse after achieving a documented response (complete response \[CR\] or complete response with incomplete hematologic recovery \[CRi\]) during the protocol-defined follow-up period.

Time frame:
From date of first dose of study drug up to 1 year
Reported as:
Count of participants · Participants
Incidence of Relapse
ParticipantsSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Incidence of Relapse9
SecondaryAllogeneic Stem Cell Transplantation (SCT) Realization Rate

Allogeneic stem cell transplantation (SCT) realization rate was measured by number and proportion of patients who underwent SCT after treatment of pembrolizumab and blinatumomab.

Time frame:
From the end of study treatment through 1 year.
Reported as:
Number · participants
Allogeneic Stem Cell Transplantation (SCT) Realization Rate
participantsSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Allogeneic Stem Cell Transplantation (SCT) Realization Rate13
SecondaryNumber and Proportion of Patients Who Start Pembrolizumab Maintenance
Time frame:
Up to 1 year

Results for this outcome have not been posted.

SecondaryNumber and Proportion of Patients Who Complete Pembrolizumab Maintenance
Time frame:
Up to 1 year

Results for this outcome have not been posted.

SecondaryMinimal Residual Disease Rate

Minimal residual disease (MRD) was measured by number and proportion of patients with CR/CRi who had confirmed minimal residual disease.

Time frame:
From the end of study treatment through 1 year.
Reported as:
Number · participants
Minimal Residual Disease Rate
participantsSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Minimal Residual Disease Rate16

Adverse events

Collected over Adverse events and all-cause mortality were monitored and assessed from the initiation of treatment through the end of protocol follow-up, up to 24 months after the end of treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Schedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV9/26 (34.6%)6/26 (23.1%)26/26 (100%)
Most frequent serious events
Most frequent serious events
EventSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
CYTOKINE RELEASE SYNDROMEImmune system disorders2/26
FEVERGeneral disorders2/26
BACK PAINMusculoskeletal and connective tissue disorders1/26
BACTEREMIAInfections and infestations1/26
DYSPNEARespiratory, thoracic and mediastinal disorders1/26
EYE INFECTIONInfections and infestations1/26
FEBRILE NEUTROPENIABlood and lymphatic system disorders1/26
HEADACHENervous system disorders1/26
SEPSISInfections and infestations1/26
Most frequent other events
Showing 10 of 194
Most frequent other events
EventSchedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
WHITE BLOOD CELL DECREASEDInvestigations25/26
NEUTROPHIL COUNT DECREASEDInvestigations24/26
ANEMIABlood and lymphatic system disorders22/26
PLATELET COUNT DECREASEDInvestigations21/26
LYMPHOCYTE COUNT DECREASEDInvestigations20/26
HYPOCALCEMIAMetabolism and nutrition disorders20/26
HYPONATREMIAMetabolism and nutrition disorders20/26
HYPOALBUMINEMIAMetabolism and nutrition disorders19/26
HYPOKALEMIAMetabolism and nutrition disorders19/26
HYPOPHOSPHATEMIAMetabolism and nutrition disorders17/26

Baseline characteristics

The study had two phases. Phase 1 used a '3+3' design to recommend the dose/schedule for Phase 2 out of schedules A and B. Accruals started with A, moving to B only when ≥2/6 DLTs seen on A. Per data collected, 0/6 DLT was seen on A in Phase 1, leading to 18 more evaluable accruals to A in Phase 2. Thus, all patients were from schedule A and assessed as a single cohort.

Age, Continuous
Age, Continuous(years)Schedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Median46 (20 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)Schedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Female9
Male17
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Schedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
Hispanic or Latino21
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Schedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White22
More than one race1
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Schedule A: Pembrolizumab 200mg and Blinatumomab 28 µg/Day† CIV
United States26
08

Study locations

1 site
09

References and documents

Publications

  • Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067. PubMed 41671463 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Jan 2025, 65 months.

Results were first posted in Nov 2026, 1 year 9 months after primary completion.

Of 81 non-industry phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 119. This study's 65 months is below that.

Counting every sponsor, half of 114 studies reached it within 79 months; a quarter within 56 and three quarters within 119.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Nov 2025 → Jan 2025 and completion Nov 2025 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2018
First posted
Apr 30, 2018
StartActual
Aug 2, 2019
Primary completionActual
Jan 31, 2025was Nov 2025
CompletionEst.
Sep 29, 2027was Nov 2025
Results first posted
Nov 17, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 17, 2026
Primary completion
Nov 11, 2025→Jan 31, 2025 (actual)
Nov 17, 2026
Study completion
Nov 11, 2025→Sep 29, 2027
Nov 17, 2026
Enrollment
36 (estimated)→26 (actual)
Nov 17, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedIncidence of toxicityDose-Limiting Toxicity (Phase 1)Time frame: Up to 42 days → From the start of initial treatment up to 35 days
  • EditedResponse Rate (Phase 2)Time frame: Up to 1 year → From the start of initial treatment till the end of protocol treatment, up to 5 cycles
Nov 17, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41671463 ↗
Nov 17, 2026
Secondary outcomes
9 edited
What changed in the outcomes
  • EditedIncidence of adverse eventsGrade 3-5 Adverse EventsTime frame: Up to 1 year → From the start of initial treatment until protocol completion, up to 24 months after the end of treatment.
  • EditedDuration of remissionRemissionTime frame: From the date of first documented response (CR/CRi) up to 1 year → From the date of first documented CR/CRi until disease progression or the end of protocol follow-up, whichever occurs first.
  • EditedTime to responseResponseTime frame: From date of first dose of study drug up to 1 year → From date of first dose of study drug up to the end of study treatment
  • EditedMedian Overall survivalSurvivalTime frame: From date of first dose of study drug up to 1 year
  • EditedAllogeneic stem cell transplantationStem Cell Transplantation (SCT) realization rateRealization RateTime frame: Up to 1 year → From the end of study treatment through 1 year.
  • EditedNumber and proportionProportion of patients who start pembrolizumab maintenancePatients Who Start Pembrolizumab MaintenanceTime frame: Up to 1 year
  • EditedNumber and proportionProportion of patients who complete pembrolizumab maintenancePatients Who Complete Pembrolizumab MaintenanceTime frame: Up to 1 year
  • EditedMinimal residual disease rate confirmed minimal residual diseaseResidual Disease RateTime frame: Up to 1 year → From the end of study treatment through 1 year.
  • ChangedBefore Event-free survivalNow Incidence of RelapseTime frame: From date of first dose of study drug up to 1 year
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41671463 ↗
    Primary completion Nov 11, 2025→Jan 31, 2025 (now actual)
    Study completion Nov 11, 2025→Sep 29, 2027
    Enrollment 36 (estimated)→26 (actual)
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedIncidence of toxicityDose-Limiting Toxicity (Phase 1)Time frame: Up to 42 days → From the start of initial treatment up to 35 days
    • EditedResponse Rate (Phase 2)Time frame: Up to 1 year → From the start of initial treatment till the end of protocol treatment, up to 5 cycles
    Secondary outcomes 9 edited
    What changed in the outcomes
    • EditedIncidence of adverse eventsGrade 3-5 Adverse EventsTime frame: Up to 1 year → From the start of initial treatment until protocol completion, up to 24 months after the end of treatment.
    • EditedDuration of remissionRemissionTime frame: From the date of first documented response (CR/CRi) up to 1 year → From the date of first documented CR/CRi until disease progression or the end of protocol follow-up, whichever occurs first.
    • EditedTime to responseResponseTime frame: From date of first dose of study drug up to 1 year → From date of first dose of study drug up to the end of study treatment
    • EditedMedian Overall survivalSurvivalTime frame: From date of first dose of study drug up to 1 year
    • EditedAllogeneic stem cell transplantationStem Cell Transplantation (SCT) realization rateRealization RateTime frame: Up to 1 year → From the end of study treatment through 1 year.
    • EditedNumber and proportionProportion of patients who start pembrolizumab maintenancePatients Who Start Pembrolizumab MaintenanceTime frame: Up to 1 year
    • EditedNumber and proportionProportion of patients who complete pembrolizumab maintenancePatients Who Complete Pembrolizumab MaintenanceTime frame: Up to 1 year
    • EditedMinimal residual disease rate confirmed minimal residual diseaseResidual Disease RateTime frame: Up to 1 year → From the end of study treatment through 1 year.
    • ChangedBefore Event-free survivalNow Incidence of RelapseTime frame: From date of first dose of study drug up to 1 year
    + 3 other changes: index terms, verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03512405
Responsible party
Sponsor
First posted
Apr 30, 2018
Start date
Aug 2, 2019
Primary completion
Jan 31, 2025
Completion
Sep 29, 2027 (estimated)
Results posted
Nov 17, 2026
Last update
Nov 17, 2026

Study contacts

Lihua Budde
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Blinatumomab · Pembrolizumab

Start the discussion